The number of Next Generation Biotherapeutics in the pipeline
and market is set to rise
• Next Generation Biotherapeutics include the latest generation of cell-based therapies, gene therapies and regenerative medicines.
• In 2018, between five and eight Next Generation Biotherapeutics will be approved and launched and, over the
next five years, these therapies will make up 20% of the 40-45 New Active Substances (NAS) projected to be
launched each year.
• In most cases, Next Generation Biotherapeutics will have costs approaching or exceeding $100,000 per patient.
The challenge both for manufacturers and payers will be to create a new payment and reimbursement paradigm
that maximizes access to these new therapies.
NUMBER of NExT gENERATIoN BIoThERApEUTICS CURRENTLY MARkETEd
oR IN LATE-STAgE pIpELINE
